After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there ...

It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...